The drugstore giant endured a challenging 2019. While full-year sales rose 4% to $137 billion, the company’s shares declined 14%, the worst performance by a Dow 30 stock. Diminished profits from generic drug sales and increased competition from the likes of Amazon and Walmart challenged the drugstore giant—and that was before the coronavirus hit, prompting many to skip doctor visits and the prescriptions that come with them. The company is countering by closing hundreds of stores to cut costs and striking more than a dozen strategic partnerships with companies including Microsoft and Kroger, as well as with Alphabet’s drone delivery service, Wing. In July, Stefano Pessina announced that he will step down as CEO and become executive chairman; a search for his successor is under way.